Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cognetivity Neurosciences Ltd. (C:CGN)

Business Focus: Medical Software & Technology Services

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for CGN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 20, 2021 09:00 ET
Cognetivity Neurosciences Granted FDA Clearance for Commercial Distribution of ICA Throughout US Healthcare Market
Completed US FDA registration of CognICA Integrated Cognitive Assessment allows the company to market its ICA as a medical device across the United States
Read full article
Oct 13, 2021 14:35 ET
Cognetivity Neurosciences Wins Health & Technology Awards and Announces Corporate Update
Company's technology awarded 'Best use of AI and Automation Tools' by The Health Tech Awards 2021 and 'Best Use of AI in the Cloud' by Cloud Excellence Awards 2021
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.01
--
--
Price to Sales - TTM
--
16.36
12.91
Price to Book - most recent quarter
--
1.63
3.21
Price to Cash Flow per share - TTM
--
12.96
13.45
Price to Free Cash Flow per share - TTM
--
28.77
32.88
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Oct 15, 2021185,765173,409
Sep 30, 202112,356-13,608
Sep 15, 202125,96422,895
See Short Report

Business Summary

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology

Cognetivity Neurosciences Ltd is Canada-based technology company, engaged in developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical and commercial environments. The ICA platform uses artificial intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of the brain, potentially allowing early diagnosis of dementia. The Company aims to develop the ICA through planned clinical studies to the market in North America and Europe.

See business summary

 

Twitter

Search (past week) for $CGN.CA

  • No tweets found